• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA )

    43.22 +1.02 (+2.42%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Vera Therapeutics, Inc. - Class A Common Stock

    < Previous 1 2 3 Next >
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Participate at Upcoming Investor Conferences
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Participate at September Investor Conferences
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.